The Senate Finance Committee today held a hearing on “tackling opioid and substance use disorders in Medicare, Medicaid and human services programs.” Chairman Orrin Hatch (R-UT) said he has already identified several areas of potential bipartisan support, including “the need to evaluate access to and utilization of non-opioid treatment options for managing pain; enhancing data-sharing to promote appropriate health care interventions and strengthen program integrity; and ensuring evidence-based care is available for patients to identify and treat opioid use disorders.” Ranking Member Ron Wyden (D-OR) called Medicaid “a key part of any solution.” He also criticized opioid drug makers and distributors for contributing to the crisis, and said “they need to be brought before this committee and held accountable.” Testifying at the hearing were Assistant Secretary for Health Brett Giroir, M.D., senior advisor to the HHS secretary on mental health and opioid policy, and Kimberly Brandt, principal deputy administrator for operations at the Centers for Medicare & Medicaid Services.

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Headline
The White House Office of National Drug Control Policy seeks by 2022 to reduce drug overdose deaths and youth illicit drug use by 15 percent and opioid…
Perspective
Investing in our country’s health infrastructure is the right move to make.
Headline
The AHA yesterday announced support for the Opioid Workforce Act of 2019, bipartisan legislation to reduce the nation’s shortage of opioid treatment providers…
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic, of which the AHA is a sponsor, held a two-day meeting this week…